Heart failure has a five-year mortality rate approaching 50%. Inducing angiogenesis
following a myocardial infarction is hypothesized to reduce cardiomyocyte death and tissue …

The 5-year mortality rate for heart failure borders on 50%. The main cause is an ischaemic
cardiac event where blood supply to the tissue is lost and cell death occurs. Over time, this …

Acute myocardial infarction (MI) caused by ischemia is the most common cause of cardiac
dysfunction. While growth factor therapy is promising, the retention in the highly vascularized …

Aims The study reports the feasibility and efficiency of vascular endothelial growth factor
(VEGF) delivery using nanoparticles synthesized from glycidyl methacrylated dextran (D ex …

Technologies to increase tissue vascularity are critically important to the fields of tissue
engineering and cardiovascular medicine. Currently, limited technologies exist to encourage …

Acute myocardial infarction (MI) caused by ischemia and reperfusion (IR) is the most
common cause of cardiac dysfunction due to local cell death and a temporally regulated …

Hyaluronic acid (HA) is used in substitutive and aesthetic medicine with various
applications. Ultrapure absorbable HA (Bioregen®) and a mix of reticulated and free low …

We investigated the angiogenic bioactivity and therapeutic angiogenic effect of vascular
endothelial growth factor (VEGF) administration by the heparin-functionalized nanoparticle …

In the last decade, numerous growth factors and biomaterials have been explored for the
treatment of myocardial infarction (MI). While pre‐clinical studies have demonstrated …

Vascular endothelial growth factor (VEGF) is a well-characterized proangiogenic cytokine
that has been shown to promote neovascularization in hearts of patients with ischemic heart …